North America & Europe Age-related Macular Degeneration Therapeutics; Depends on the Type of the Condition (Dry/Wet)
North America & Europe Age-related Macular Degeneration Therapeutics North America & Europe age-related macular degeneration therapeutics depends on the type of the condition. There are two types of age-related macular degeneration, such as wet age-related macular degeneration and dry age-related macular degeneration. Age-related macular degeneration (AMD) is an eye disease that causes vision loss, due to the thinning of the macula of the retina. Currently, the most common and effective North America & Europe age-related macular degeneration therapeutics is anti-VEGF therapy, a periodic Intravitreal injection (into the eye) of a chemical called an anti-VEGF. The promising new treatment involves retinal gene therapy, which aims to employ the body to make its own anti-VEGF by inserting a harmless virus (called an adeno-associated virus/AAV) carrying the anti-VEGF gene into a person's DNA. Wet AMD can be managed through anti-vascular endothelial growth factor (anti-VEGF) injections. Whereas, in dry AMD, macula gets thinner with increasing age leading to the vision loss. However, there is no available treatment for dry agerelated macular degeneration. AMD (both dry and wet) typically occurs in geriatric population and can cause permanent vision loss in people of age 60 and above. Read More: https://www.linkedin.com/pulse/north-america-europe-age-related-maculardegeneration-vishwakarma/
North America & Europe Age-related Macular Degeneration Therapeutics; Depends on the Type of the Condition (Dry/Wet)
North America & Europe Age-related Macular Degeneration Therapeutics; Depends on the Type of the Condition (Dry/Wet)
North America & Europe Age-relat...